Skip to content
OpenCapital
Get started

Organon OGN Singulair — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

AbbVie logo
ABBVSkyrizi — Net revenues
$4.48B+30.9%
Incyte logo
INCYICLUSIG — Total revenues
$35.46M+20.0%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Bristol-Myers Squibb logo
BMYSprycel — Total Revenues
$73M-58.3%
ResMed logo
RMDSleep and Breathing Health — Net revenue
$1.26B+11.5%
Indivior Pharmaceuticals, Inc. logo
INDVSublingual & other — Net revenue
$50M-7.4%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's singulair — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's singulair — revenue?
Organon (OGN) reported singulair — revenue of $40M in Q1 2026.
How has Organon's singulair — revenue changed year-over-year?
Organon's singulair — revenue decreased by 45.9% year-over-year, from $74M to $40M.
What is the long-term trend for Organon's singulair — revenue?
Over 4 years (2021 to 2025), Organon's singulair — revenue has grown at a -11.6% compound annual growth rate (CAGR), from $412M to $252M.
What does singulair — revenue mean?
This metric represents the total net sales generated by the Singulair product line within the established medicines portfolio. It reflects the market demand and commercial performance of this specific respiratory therapy asset over a given fiscal period. Monitoring these revenues helps investors assess the lifecycle stage and contribution of mature pharmaceutical products to the company's overall top-line results.